Skip to main content

Table 5 Pattern of compliance to chemotherapy by age and radiotherapy

From: Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

Variable

Age

Radiotherapy

 

>60 and < 65 (n = 100)

≥ 65 (n = 80)

P§

No* (n = 114)

Yes (n = 66)

P§

N. of cycles administered, no. (%)

  

0.42

  

0.01

6 cycles

81 (81)

61 (76)

 

84 (74)

58 (88)

 

5 cycles

5 (5)

4 (5)

 

4 (3)

5 (8)

 

4 cycles

4 (4)

4 (5)

 

6 (5)

2 (3)

 

3 cycles

5 (5)

6 (8)

 

10 (9)

1 (1)

 

2 cycles

4 (4)

4 (5)

 

8 (7)

0

 

1 cycle

1 (1)

1 (1)

 

2 (2)

0

 

N. of day 8 omitted, no. (%)

  

0.37

  

0.86

0

69 (69)

51 (64)

 

77 (68)

43 (65)

 

1

23 (23)

18 (22)

 

24 (21)

17 (26)

 

2

5 (5)

8 (10)

 

9 (8)

4 (6)

 

3

3 (3)

3 (4)

 

4 (3)

2 (3)

 

Rate of cycles at reduced dose, no. (%)

  

0.54

  

0.83

≤ 25%

86 (86)

66 (82)

 

97 (85)

55 (83)

 

>25%

14 (14)

14 (18)

 

17 (15)

11 (17)

 

Actual/planned duration, no. (%)

  

0.59

  

0.05

≤ 1.25

99 (99)

78 (98)

 

114 (100)

63 (95)

 

>1.25

1 (1)

2 (2)

 

0

3 (5)

 

G-CSF utilization, no. (%)

  

0.12

 

<.0001

 

No

91 (91)

66 (82)

 

109 (96)

48 (73)

 

Yes

9 (9)

14 (18)

 

5 (4)

18 (27)

 

Treatment discontinuation, no. (%)

  

0.52

  

0.10

protocol completion

81 (81)

61 (76)

 

84 (74)

58 (88)

 

patient's refusal

6 (6)

9 (11)

 

12 (11)

3 (4)

 

treatment toxicity

11 (11)

7 (9)

 

13 (11)

5 (8)

 

other

2 (2)

3 (4)

 

5 (4)

0

 

Low compliance, no. (%)

  

0.02

  

0.88

No

61 (61)

34 (42)

 

61 (54)

34 (52)

 

yes

39 (39)

46 (58)

 

53 (46)

32 (48)

 
  1. * including 21 patients who received radiotherapy after the end of chemotherapy
  2. § Fisher exact test or Wilcoxon-Mann Whitney test for naturally ordered variables)
  3. † at least one of the following features: less than 6 cycles administered, withdrawal of more than one day-8 treatment, dose reduction in more than 25% of cycles, relative duration higher than 1.25, use of G-CSF treatment, treatment interruption because of patient's refusal or toxicity